Adagene Inc.

General Information

We are a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Our platform is designed to generate therapeutic antibody candidates with unique functional epitopes and species cross-reactivity as highlighted by our immunotherapy pipeline. 

(Note: Adagene priced its IPO on Feb. 8, 2021, at $19 – the top of its $17-to-$19 range – on the same number of shares, 7.35 million, as stated in the prospectus.)

Industry: Pharmaceuticals
Employees: 198
Founded: 2011
Contact Information
Address 4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People's Republic of China
Phone Number +86-512-8777-3632
Web Address
View Prospectus: Adagene Inc.
Financial Information
Market Cap
Revenues $0 mil (last 12 months)
Net Income $-34.24 mil (last 12 months)
IPO Profile
Symbol ADAG
Exchange NASDAQ
Shares (millions): 7.4
Price range $19.00 - $19.00
Est. $ Volume $139.7 mil
Manager / Joint Managers Goldman Sachs/ Morgan Stanley/ Jefferies
CO-Managers China Renaissance
Expected To Trade: 2/9/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change